USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
MEDICON, INC.
Address:
18 Blueberry Ridge Rd
Setauket, NY
Phone:
N/A
URL:
N/A
EIN:
113387183
DUNS:
616767807
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $649,698.00 3
STTR Phase I $187,534.00 1
STTR Phase II $1,803,865.00 1

Award List:

Novel Urea Breath Test for H. Pylori Diagnosis

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$149,800.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): We propose to develop a novel method for the diagnosis of Helicobacter pylori. The diagnosis of H. pylori infection is a high medical priority because: this bacterium infects approximately 50% of the world's population; causes peptic ulcer disease, gastric… More

Not Available

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$199,899.00
Agency:
HHS
Principal Investigator:
Despina Komninou
Abstract:
We propose studies for the preclinical development of BJ-813, a novel agent against breast cancer. BJ-813 has significant activity in vitro (human breast cancer cell lines covering the clinical spectrum of the disease) and in xenograft models of human breast cancer in nude mice. When formulated in… More

MDC-1231 for cancer prevention

Award Year / Program / Phase:
2010 / STTR / Phase I
Award Amount:
$187,534.00
Agency:
HHS
Principal Investigator:
Basil Rigas – 631-444-9538
Research Institution:
State University New York Stony Brook
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): Strong evidence supports the notion that chemoprevention has the potential to be a major component of colorectal cancer control. The prevention of cancer depends heavily on the development of safe and effective agents.NSAIDs prevent colorectal cancer but have two… More

MDC-1231 for cancer prevention

Award Year / Program / Phase:
2012 / STTR / Phase II
Award Amount:
$1,803,865.00
Agency:
HHS
Principal Investigator:
Basil Rigas – 631-444-9538
Research Institution:
STATE UNIVERSITY NEW YORK STONY BROOK
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): The chemoprevention of colon cancer has been hampered by either weak agents or significant side effects. It was recently shown that the combination of sulindac with difluoromethylornithine (DFMO) prevents nearly 70% ofcolon cancer, assessed as colon polyp… More

An agent for the treatment of lung cancer

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$299,999.00
Agency:
HHS
Principal Investigator:
Despina Komninou – 631-751-0577
Abstract:
DESCRIPTION (provided by applicant): Lung cancer is the leading cause of cancer deaths in the US and worldwide. Given its prevalence, morbidity and mortality, it is clear that in terms of treatment, the lung cancer problem is far from solved; and thatnew agents are urgently needed. Our… More